- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05727839
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase
1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Guangzhou
-
Guangdong, Guangzhou, China, 510060
- Recruiting
- Sun Yat-Sen University Cancer Center
-
Contact:
- Xu R hua, professor
- Email: ruihxu@163.com
-
Contact:
- ruan dan yun, physician
- Phone Number: 13760611470
- Email: ruandy1@sysucc.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients 18-75
- Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology
- Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist
- Patients with at least one non-injected measurable tumor lesion per RECIST v1.1
- Patients with lesions suitable for intratumoral injection (the lesion length is at least 10mm and not exceeding 80mm)
- Patients enrolled in the Skin/subcutaneous lesions and deep (visceral) lesions stages of Phase Ia must agree to provide pre- and post-treatment tumor biopsy tissues
- Patients must have adequate organ and marrow functions
- Patients with treated brain metastases are eligible if meeting protocol's requirement
- Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy
Exclusion Criteria:
- Patients who have received prior IL-12 either alone or as part of a treatment regimen
- Patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)
- Patients requiring therapeutic doses of anticoagulation
- Patients with tumors that impinge on major airways, blood vessels, or nerve bundles
- Patients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications
- Patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment
- Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment
- Patient with history of solid organ or allogenic bone marrow transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase Ia:Dose escalation
JCXH-211 will be delivered by intratumoral injection in 2 stages: (Part1)Intratumoral injection stage of skin/subcutaneous lesions. According to Part 1 study results,1-2 dose groups were selected for deep lesion injection study, dose escalation will follow the "3 + 3" principle. |
JCXH-211 administered once every 28 days
Other Names:
|
Experimental: Phase Ib: Dose Extension
JCXH-211 will be delivered by intratumoral injection.
The dose to be used will be determined after review of the data from Phase Ia.
|
JCXH-211 administered once every 28 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicity
Time Frame: Within 28 days after the first dose
|
Dose limiting toxicity, evaluated in the Phase Ia, which will be used to determine the MTD and to determine dose escalation.
|
Within 28 days after the first dose
|
Incidence of adverse events (Safety and Tolerability)
Time Frame: From consent to 28 days after the last dose of study drug
|
Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs).
|
From consent to 28 days after the last dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 12 months
|
Objective response rate is defined as the proportion of patients that achieve a complete response (CR) or partial response (PR) during the study participation.
|
Up to 12 months
|
Duration of response (DoR)
Time Frame: Up to 12 months following first reported response
|
Duration of response is defined as the time from the first assessment of tumor as CR or PR to the first assessment as progressive disease or death from any cause.
|
Up to 12 months following first reported response
|
Disease control rate (DCR)
Time Frame: Up to 12 months
|
Disease control rate is defined as the proportion of patients with CR or PR or stable disease (SD) with the DoR ≥ 12weeks observed from Day 1 to disease progression.
|
Up to 12 months
|
Time to response (TTR)
Time Frame: Up to 12 months from the start of study therapy
|
Time to response is defined as the time from Day 1 until the first documentation of objective response (CR or PR).
|
Up to 12 months from the start of study therapy
|
Progression-free survival (PFS)
Time Frame: Up to 12 months
|
Progression-free survival is defined as the time from Day 1 to disease progression or death from any cause, whichever occurs earlier.
|
Up to 12 months
|
Overall survival (OS)
Time Frame: Up to 24 months
|
Overall survival is defined as the time from Day 1 until death due to any cause.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JCXH-211-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Solid Tumor
-
Daiichi Sankyo Co., Ltd.RecruitingAdvanced Solid Tumor | Malignant Solid TumorUnited States, Japan
-
Elpiscience Biopharma, Ltd.Shanghai Junshi Bioscience Co., Ltd.RecruitingNeoplasms | Solid Tumor | Malignant TumorChina
-
Bristol-Myers SquibbCompletedMalignant Solid TumorUnited States, France, Italy, Australia, Canada, Germany, Netherlands
-
Nektar TherapeuticsCompletedMalignant Solid TumorUnited States, Belgium
-
Medical University of ViennaUnknown
-
Aadi Bioscience, Inc.RecruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmKorea, Republic of, United States, Puerto Rico
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
Peregrine PharmaceuticalsTerminatedMalignant Solid TumorUnited States
-
Shanghai Acebright Pharmaceuticals Co., Ltd.UnknownMalignant Advanced Solid TumorChina
-
Eli Lilly and CompanyCompletedMalignant Solid TumorUnited States
Clinical Trials on JCXH-211 Injection
-
Immorna Biotherapeutics, Inc.Active, not recruitingMalignant Solid Tumor | Cutaneous TumorUnited States
-
Peking University Cancer Hospital & InstituteRecruitingAdvanced Malignant Solid TumorsChina
-
Andrea WallaceAgency for Healthcare Research and Quality (AHRQ)Completed
-
Affini-T Therapeutics, Inc.RecruitingColorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Pancreatic Ductal Adenocarcinoma | KRAS G12VUnited States
-
AmgenMedImmune LLCTerminatedGI AdenocarcinomaGermany, Netherlands
-
Immorna Biotherapeutics, Inc.ICON plcRecruitingCOVID-19 | Infectious DiseaseUnited States
-
Immorna Biotherapeutics, Inc.ICON plcActive, not recruitingInfectious Disease | Shingles | Herpes Zoster (HZ)United States
-
University of California, San FranciscoCompletedConditions Influencing Health Status | Social Determinants of HealthUnited States
-
Vastra Gotaland RegionThe Swedish Research Council; Sahlgrenska University Hospital, Sweden; Swedish...Completed
-
Astellas Pharma IncOSI PharmaceuticalsCompletedSCLC | Carcinoma, Small CellUnited Kingdom, United States